Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study
| Autor: | Xu, Peng-Peng a, *, Shi, Zi-Yang a, *, Qian, Ying a, *, Cheng, Shu a, Zhu, Yue a, Jiang, Lu a, Li, Jian-Feng a, Fang, Hai a, Huang, Heng-Ye c, Yi, Hong-Mei b, Ouyang, Bin-Sheng b, Wang, Li a, d, Zhao, Wei-Li a, d, * |
|---|---|
| Zdroj: | In The Lancet Healthy Longevity July 2022 3(7):e481-e490 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|